RecruitingEarly Phase 1NCT06470295

Effect of C-peptide on Hypoglycemic Counterregulation

On the Regulation of Hepatic Glucose Metabolism During Insulin-induced Hypoglycemia

Sponsor

University of Cincinnati

Enrollment

38 participants

Start Date

Jun 1, 2024

Study Type

INTERVENTIONAL

Conditions

Type 1 Diabetes Hypoglycemia

Summary

Iatrogenic hypoglycemia is the most prominent barrier to the safe, effective management of blood sugar in people with type 1 diabetes due to periodic over-insulinization. During insulin-induced hypoglycemia, glucagon secretion is diminished in type 1 diabetes which, in turn, reduces hepatic glucose production and increases the depth and duration of hypoglycemic episodes. We have observed that the naturally occurring protein C-peptide increases glucagon secretion in dogs during insulin-induced hypoglycemia, which increases hepatic glucose production; the experiments in this application will shed light on the translation of this finding to the human.

Eligibility

Min Age: 18 YearsMax Age: 40 Years

Plain Language Summary

Simplified for easier understanding

This study is testing whether C-peptide (a natural protein made alongside insulin in the pancreas) affects how the body responds when blood sugar drops too low (hypoglycemia), which is a common and dangerous problem for people with diabetes. **You may be eligible if...** - Your BMI is less than 30 - You do not smoke - You are otherwise healthy **You may NOT be eligible if...** - You are pregnant or breastfeeding - You smoke cigarettes - You have HIV or hepatitis - You have cardiovascular (heart or blood vessel) disease - You have microvascular disease (damage to small blood vessels, such as in eyes or kidneys) Talk to your doctor to see if this trial is right for you.

This summary was AI-generated to explain the trial in plain language. It is not medical advice. Always discuss eligibility with your doctor before enrolling in a clinical trial.

Interested in this trial?

Get notified about updates and connect with the research team.